Pharma channel feed

At­ul Gawande takes aim at surg­ing pre­scrip­tion drug costs as chief of cryp­tic Buf­fett-Be­zos-Di­mon ven­ture now chris­tened 'Haven'

7 years ago
Financing

Fol­low­ing key late-stage ad­vances, BeiGene puts down $10M to get some dis­cov­ery projects rolling at Am­brx

7 years ago
R&D

J&J wins FDA OK for their nasal spray ver­sion of a par­ty drug, now ap­proved for treat­ment-re­sis­tant ma­jor de­pres­sion

7 years ago

Pop­u­lar FDA com­mish Scott Got­tlieb has hand­ed in his res­ig­na­tion

7 years ago
People

The drug pric­ing de­bate in Amer­i­ca reach­es a boil­ing point at #JPM19

7 years ago

Cit­ing lin­ger­ing con­cerns, FDA stops Evoke at the 10-yard line a month be­fore PDU­FA date

7 years ago

With $1.4B bet rid­ing on their de­ci­sion, myelofi­bro­sis drug left for dead by Sanofi hits FDA's in­side track to a block­buster come­back

7 years ago

Sen­a­tors seek changes to FDA guid­ance to speed en­try of in­sulin biosim­i­lars

7 years ago

Ver­tex’s 3-year feud with NICE is about to come to a head as CEO Lei­den heads to Lon­don

7 years ago

Team build­ing. Pipeline re­vamp. For­ward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with Chi­na's NJCT­TQ, with eyes on bis­pe­cif­ic T cell en­gagers

7 years ago
China

Pfiz­er’s block­buster safe­ty is­sue jumps the At­lantic as EMA launch­es its own re­view of Xel­janz

7 years ago

Af­ter a slate of small, tack-on ac­qui­si­tions, is Mer­ck ready to pull the trig­ger on a big M&A deal?

7 years ago

Got­tlieb tes­ti­fies on sta­tus of FDA op­er­a­tions af­ter gov­ern­ment shut­down

7 years ago

Michael Co­hen on No­var­tis ties: '(T)hey want­ed me to pro­vide ac­cess to gov­ern­ment, in­clud­ing the pres­i­den­t'

7 years ago

No­var­tis, Ab­b­Vie dom­i­nate the top 10 list of block­busters prep­ping for a 2019 mar­ket­ing launch

7 years ago

FDA hands back Adamis' ap­pli­ca­tion for an ED drug, look­ing for more da­ta

7 years ago

Parex­el re­cruits top FDA on­col­o­gy ex­pert Amy Mc­K­ee for new R&D ini­tia­tive

7 years ago
People

FDA ex­perts turn thumbs down on Karyopharm’s trou­bled pitch for an ac­cel­er­at­ed OK — but not all of them

7 years ago

In land­mark hear­ing, drug­mak­ers and law­mak­ers agree that US pol­i­cy on drug pric­ing is ripe for change — but there's no con­sen­sus on much else

7 years ago

Is the $74B Cel­gene buy­out al­ready forc­ing a reck­on­ing among Bris­tol-My­ers Squibb’s R&D part­ners?

7 years ago
Deals

Ad­di­tion­al ex­clu­siv­i­ty for a can­cer treat­ment could cost the pub­lic $3 bil­lion, an­a­lyst says

7 years ago

FDA sounds the alarm on Pfiz­er’s block­buster Xel­janz af­ter a high dose was linked to a high­er death rate, blood clots

7 years ago
R&D

Dana­her hands a dis­tressed GE $21B+ for bio­phar­ma busi­ness that made $3B last year

7 years ago
First page Previous page 278279280281282283284 Next page Last page
A service from the Financial Times